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Abstract
Quantification of sickle hemoglobin (HbS) in patients with sickle cell disease (SCD) undergoing 
hydroxyurea or chronic transfusion therapy is essential to monitoring the effectiveness of these 
therapies. The clinical monitoring of %HbS using conventional laboratory methods is limited by 
high per-test costs and long turnaround times usually associated with these methods. Here we 
demonstrate a simple, rapid, inexpensive paper-based assay capable of quantifying %HbS in blood 
samples from patients with SCD. A 20 μL droplet of whole blood and hemoglobin solubility 
buffer was deposited on chromatography paper. The relative color intensities of regions of the 
resulting blood stain, determined by automated image analysis, are used to estimate %HbS. We 
compared the paper-based assay with hemoglobin electrophoresis (comparison method) using 
blood samples from 88 subjects. The test shows high correlation (R2 = 0.86) and strong agreement 
(standard deviation of difference = 7 %HbS) with conventional Hb electrophoresis measurement 
of %HbS, and closely approximates clinically predicted change in %HbS with transfusion therapy 
(mean difference 2.6 %HbS, n = 4). The paper-based assay can be completed in less than 35 
minutes and has a per-test cost less than $0.25. The assay is accurate across a wide range of HbS 
levels (10–97%) and hemoglobin concentrations (5.6–12.9 g/dL) and is unaffected by high levels 
of HbF (up to 80.6%). This study demonstrates the feasibility of the paper-based %HbS assay. The 
paper-based test could improve clinical care for SCD, particularly in resource-limited settings, by 
enabling more rapid and less expensive %HbS monitoring.
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Introduction
Sickle cell disease (SCD) is a common recessively inherited blood disorder caused by a 
point mutation of the β-globin gene.(1) Unlike normal adult hemoglobin (HbA), sickle 
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hemoglobin (HbS) polymerizes and becomes insoluble under hypoxic conditions, causing a 
number of structural and functional abnormalities in affected red blood cells (RBCs). 
Sickled RBCs have increased fragility and rigidity that render them prone to early 
breakdown and occlusion of blood vessels. Patients with SCD experience chronic hemolytic 
anemia, episodic pain crises and abnormal blood flow to critical organs that cumulatively 
result in significant illness and shortened lifespans.(2) Although, the severity of the disease 
varies greatly among patients, for each individual patient the rate of adverse events is 
strongly correlated with the intraerythrocytic concentration of HbS.(1)
The two main therapeutic options for SCD, hydroxyurea and chronic transfusion, both rely 
primarily on a reduction of the relative HbS level for their beneficial effect. Hydroxyurea 
induces the expression of hemoglobin F (HbF) in erythrocytes, reducing the 
intraerythrocytic HbS concentration and making the erythrocyte less likely to sickle in 
hypoxic conditions. Chronic transfusion therapy does not affect intraerythrocytic HbS 
concentration but reduces the overall proportion of sickle erythrocytes and partially corrects 
the anemia of SCD, improving organ perfusion and oxygenation.(3) The main goal of 
chronic RBC transfusion for SCD patients is to maintain a low level of HbS (<30%) in order 
to decrease the rate of adverse clinical outcomes, in particular the risk of primary or 
secondary stroke.(4–6) Generally, the transfusion of 2–3 RBC units or 10–15 mL/kg every 
3–5 weeks is sufficient to keep the %HbS below 30% and the [Hb] at 9–10 g/dL and 
minimize the risk of progressive complications.(7)
Both hydroxyurea and chronic transfusion therapy require frequent monitoring of the 
relative HbS concentration to assess effectiveness of therapy. The monitoring of %HbS in 
patients on these therapies using conventional laboratory methods (e.g. Hb 
electrophoresis(8) and HPLC(9)) is impeded by the high cost and long processing time 
usually associated with these methods.(8) Typically, results are not available rapidly enough 
to guide clinical decision-making at the time of the clinic visit. Additionally, since HbS 
levels are not routinely measured during or after transfusions, relatively little is known about 
the evolution of HbS levels in SCD patients on chronic transfusion therapy. A rapid, 
inexpensive assay for measuring HbS concentration in patient blood samples could be useful 
in monitoring the effectiveness of hydroxyurea and transfusion therapy by enabling more 
frequent testing than currently possible with conventional laboratory methods, thereby 
providing additional information that could inform clinical decision making.
Our research group has recently developed a low-cost paper-based test for diagnosing SCD 
in resource-limited settings.(10) This test utilizes the separation of HbS and non-sickle 
hemoglobin by differential wicking in a paper matrix to qualitatively diagnose SCD. We 
postulated that a similar test could be capable of quantifying the sickle component of total 
hemoglobin in patient blood samples. In this study, we demonstrate that this paper-based test 
can be used to rapidly and accurately quantify the HbS content in SCD patients on chronic 
transfusion and hydroxyurea therapy, as well as in infants with a relatively high endogenous 
level of Hb F.
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Methods
Blood samples
Venous blood samples were collected from patients with SCD, after informed consent 
following an IRB-approved protocol, during clinic visits (January 2013 – September 2014) 
at the Texas Children’s Hematology Center (Houston, TX). Healthy, consenting volunteers 
donated normal venous blood samples. Blood samples were collected in Vacutainer tubes 
(K2EDTA, BD, Franklin Lakes, NJ), stored between 4–25°C and analyzed within 21 days 
after collection (mean storage time before analysis = 6.4 ± 3.6 days). Sample storage time up 
to 21 days was only weakly correlated with assay performance (R2 = 0.09, p < 0.01).
Hemoglobin Electrophoresis
Hemoglobin A, F, C and S for each sample were measured using conventional Hb 
electrophoresis performed on the semi-automated Sebia Hydrasys 2 Scan system (Sebia Inc., 
Norcross, GA). All materials were prepared and run according to manufacturer 
specifications. Phoresis curve editing software (Sebia Inc., Norcross, GA) was used to 
calculate hemoglobin composition. For post-transfusion samples, the expected %HbS was 
calculated using the following method: Post-transfusion %HbS = Total HbS (g) x 100 / 
(Total post-transfusion Hb (g)); Total HbS = Pre-transfusion [Hb] x pre-transfusion %HbS x 
Total blood volume (dl); Total post-transfusion Hb = (Pre-transfusion [Hb] x total blood 
volume (dl)) + (Total transfused volume (dl) x [Hb]Transfused blood).
Hemoglobin solubility buffer
The Hb solubility buffer was a mixture of a hemolytic agent (saponin), a reducing agent 
(sodium hydrosulfite) and a high-phosphate buffer. The high-phosphate buffer (2.49M) 
consisted of 1.24M (169 g/L) monobasic and 1.25M (217 g/L) dibasic potassium phosphate 
dissolved in deionized water. The saponin (4 g/L) permeabilizes red cell membranes, 
releasing Hb into the solution. The sodium hydrosulfite (30 g/L) converts the released Hb 
into deoxy-Hb. Converted HbA, HbE, HbF and HbC remain soluble in the high-phosphate 
buffer, while deoxy-HbS polymerizes and precipitates.(11, 12)
Quantification of the blood stain color intensities
The blood stains on patterned chromatography paper were digitized by scanning the paper 
with a portable flatbed scanner (CanoScan LiDE110, Canon USA Inc, Lake Success, NY). 
The digitized blood stains were analyzed with a custom image analysis algorithm 
(MATLAB, The Math Works Inc, Natick, MA). The algorithm automatically isolates 
features of the blood stain via contrast stretching and thresholding, then calculates the mean 
color intensity of each feature using RGB color data from the Blue (B) channel of each pixel 
within the feature (color intensity = 255 – B).(13)
The relationship between the quotient of relative mean color intensities of the standardized 
blood stains and HbS content in patient samples was determined using a series of 
reconstituted blood samples with %HbS artificially adjusted from 0 – 75%. These 
calibration samples were created by mixing ABORh-matched, equal-hematocrit normal 
(HbAA) and SCD (HbSS) blood samples at various ratios to achieve the desired HbS 
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concentrations. %HbS of artificially adjusted samples was verified by Hb electrophoresis. 
Figure 2b shows this calibration curve relating the quotient of mean color intensities to 
%HbS, an exponential curve was fit to the data, where estimated %HbS = 0.332 * ln(0.639 * 
IC/IR). This calibration curve was used throughout the rest of this study to convert IC/IR to 
estimated %HbS.
Results
The design and operation of the paper-based assay for SCD has been previously described in 
detail.(10) Briefly, to perform the assay 20 μL of whole blood was added to 200 μL of 
solubility buffer, mixed by inversion, and allowed to sit for 10 minutes, to allow RBC lysis 
and hemoglobin deoxygenation. At the end of this period, 20 μL of the lysate was pipetted 
onto chromatography paper and allowed to wick laterally and dry for 25 minutes (Figure 
1a). The entire assay was performed indoors, in ambient conditions (temperature 15°C to 
25°C, 20% to 70% humidity, fluorescent lighting). The difference in transport of soluble and 
insoluble variants of hemoglobin (Hb) through the paper substrate produces a blood stain 
consisting of two parts: the area of the initial drop where polymerized deoxy-HbS is retained 
(center spot), and the area where all soluble forms of Hb are wicked laterally (peripheral 
ring). The color intensity of the center spot relative to that of the peripheral ring is indicative 
of the HbS level in the blood sample. Figure 1b shows representative blood stains for 
samples artificially reconstituted with %HbS varying from 0 to 75%. As expected, 
increasing HbS content results in increased color intensity of the center spot and decreased 
intensity of the peripheral ring. The absolute color intensity of the stain is dependent on the 
Hb concentration of the sample, but the relative color intensities of the center spot and 
peripheral ring are independent of Hb concentration. The resulting blood stain is digitized 
using a portable flatbed scanner (in reflected light) and analyzed with a custom image 
analysis algorithm. The entire assay can be performed for up to 20 samples in less than 35 
minutes.
Figure 2 describes the process of estimating %HbS based on the relative color intensity of 
the center spot and the peripheral ring areas of the blood stain. First, the custom image 
analysis algorithm applies a standard contrast stretching and thresholding routine to the 
digitized image of the blood stain to determine the center of the stain (Figure 2a-i). A 
standardized binary mask(14) is then used to isolate the appropriate parts of the blood stain 
image to calculate, IC, the mean color intensity of the center spot (Figure 2a-ii) and, IR, the 
mean color intensity of the peripheral ring (Figure 2a-iii). For each sample, the quotient of 
these two values (IC/IR) is then converted to estimated %HbS using the equation (estimated 
%HbS = 0.332 * ln(0.639 * IC/IR)) derived from the calibration curve (Figure 2b).
To test the accuracy of our paper-based quantification method, we then compared the value 
of %HbS in individual patient samples measured by conventional Hb electrophoresis (Sebia 
Hydrasys 2 Scan, Sebia Inc., Norcross, GA) and by the paper-based assay. Of the 88 
samples used in this analysis, 55 were from patients on hydroxyurea therapy, 25 were from 
patients on chronic transfusion therapy, and 8 were from infants. The ages of the patients 
ranged from one month to 18.8 years, hemoglobin concentrations ranged from 5.6 to 12.9 
g/dL, and %HbS ranged from 10 to 97%. Five patients had the SC genotype, 3 patients had 
Piety et al. Page 4
Am J Hematol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
the Sβ0 genotype, and 2 patients had the Sβ+ genotype. As shown in Figure 3a, the values of 
%HbS estimated using the paper-based assay (Estimated %HbS) and measured using 
conventional hemoglobin electrophoresis (Actual %HbS) were highly correlated (R2 = 
0.86). When broken down by sample type, the correlation between %HbS measured by 
electrophoresis and that measured by the paper-based assay remained high, although the 
correlation was weaker for patients undergoing hydroxyurea therapy (R2hydroxyurea = 0.61, 
R2transfusion = 0.87, R2infant = 0.83), indicating that the accuracy of the paper-based assay 
was not affected by significant variations in %HbS and %HbA, and %HbF or by the relative 
distribution of these hemoglobin complexes within erythrocytes. The lower correlation for 
patients undergoing hydroxyurea therapy resulted from decreased accuracy of the test at 
very high %HbS levels (the samples from patients undergoing hydroxyurea therapy tended 
to have the highest HbS concentrations) rather than from inherent differences between 
patient groups.
Figure 3b shows a Bland-Altman plot(15) of the %HbS values obtained using both methods. 
The values of %HbS for patient samples estimated using the paper-based assay and 
measured using conventional hemoglobin electrophoresis show strong agreement. The 
standard deviation of the differences between different %HbS values obtained using both 
methods was 7 %HbS. The majority (95.5%) of the differences between actual and 
estimated %HbS are within 2 standard deviations of the mean of the differences. The limits 
of agreement between the paper-based HbS assay and conventional hemoglobin 
electrophoresis were −11.5 %HbS and 17.0 %HbS. The paper-based HbS assay agreed with 
the hemoglobin electrophoresis system within 5 %HbS 58.0% of the time, overestimating 
%HbS by >5 %HbS in 10.2% of subjects and underestimating %HbS by >5 %HbS in 31.8% 
of subjects.
We tested the repeatability of the paper-based method for quantifying HbS by repeatedly 
measuring (n = 5) the %HbS for a series of blood samples with HbS content of 
approximately 10, 20, 30, 40, 50, 60, 70 and 80 %HbS. The standard deviation for the 
%HbS measurements performed with different droplets of the same blood sample was 
consistently < 1.5 %HbS for all values of %HbS measured: 0.9 %HbS (CV 6.3%) for the 
sample with 10 %HbS; 1.0 %HbS (CV 4.8%) for 20 %HbS; 1.3 %HbS (CV 4.1%) for 30 
%HbS; 1.1 %HbS (CV 2.6%) for 40 %HbS; 0.7 %HbS (CV 1.3%) for 50 %HbS; 1.3 %HbS 
(CV 2.1%) for 60 %HbS; 1.1 %HbS (CV 1.6%) for 70 %HbS; and 1.5 %HbS (CV 1.9%) for 
80 %HbS. For comparison, the standard deviations for the %HbS measurements performed 
by the manufacturer of the Sebia Hydrasys 2 Scan system for blood samples with %HbS 
ranging from 8.8 – 83.6 %HbS was 0.2 – 0.6 %HbS (CV 0.7 – 2.1%).
Finally, to assess the utility of the paper-based assay in measuring the change in %HbS with 
transfusion therapy, we compared the change in %HbS in five patients based on pre- and 
post-transfusion measurements made using Hb electrophoresis to the same measurements 
made using the paper-based assay and to an estimate of post-transfusion %HbS made using 
a formula currently used to guide clinical transfusion practices (based on patient weight, Hb 
concentration and initial %HbS). As presented in Table 1, the change in %HbS with 
transfusion measured by Hb electrophoresis was very close to both that estimated by the 
clinical formula (mean difference 3.3 %HbS) and that measured with the rapid assay (mean 
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difference 3.9 %HbS) for all five patients, indicating that our paper-based assay is capable 
of accurately determining changes in %HbS following transfusion therapy.
Discussion
In this report, we present a novel paper-based method of quantifying HbS levels in blood 
samples from patients with sickle cell disease. Our method is based on the previously 
described qualitative diagnostic test for sickle cell disease that relies on the differential 
wicking of insoluble HbS and soluble non-sickle hemoglobins on a paper substrate to 
produce characteristic blood stain patterns. We now extend this method to permit the 
quantification of sickle hemoglobin using the patterns produced by this diagnostic test. This 
quantification is effected by digitization of the rapid test paper containing the blood stain 
and measurement of the relative color intensity of the center spot, composed of trapped, 
precipitated sickle hemoglobin, and the peripheral ring, composed of free, soluble 
hemoglobins. As indicated by the data presented above, quantification of %HbS by this 
method is highly accurate and reproducible relative to conventional hemoglobin 
electrophoresis. This method is also accurate across a wide range of HbS levels and 
hemoglobin concentrations and is unaffected by high levels of endogenous HbF or 
exogenous HbA. As such, it is potentially applicable to monitor any therapeutic modality 
that alters the relative level of HbS, including acute or chronic transfusion therapy and 
hydroxyurea therapy.
Our paper-based assay offers several advantages over conventional methods for the 
quantification of HbS. The first and most prominent is the low cost of our assay. The cost of 
consumable materials and reagents for our test is less than $0.25 per sample, and the initial 
investment for a computer and scanner for image digitization is less than $400. By contrast, 
the cost of required supplies for the conventional hemoglobin electrophoresis system used as 
a reference standard in our laboratory is $1,800 annually for system solutions and controls, 
plus an additional $5.77 to $12.07 per sample for consumable materials and reagents, and 
the initial investment for the system is more than $20,000. The estimated cost per sample of 
both IEF and HPLC at our collaborating center is approximately $60. Our rapid assay thus 
offers significant cost savings compared to other methods of HbS quantitation.
A second advantage of our paper-based assay is the ease of use of the system. Processing of 
blood samples to develop the blood stain is a simple operation requiring only two steps 
(mixing and sample deposition). Subsequent digitization and quantification of the blood 
stain itself is also straightforward and is largely accomplished by the automated image 
analysis algorithm. The overall process of blood stain development, image scanning, and 
HbS quantification can therefore be performed with minimal technical training by any 
operator with basic laboratory skills.
A final advantage of the paper-based assay is the rapidity of the assay. Conventional 
laboratory methods of hemoglobin quantification can be completed rapidly, but due to the 
limited availability of clinical technicians and costs associated with sample processing, 
samples are often grouped to be run in large batches, delaying the availability of results. In 
contrast, our paper-based assay does not require batching and has an extremely low per-test 
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cost, even for single samples. A sample obtained from a patient can be processed, digitized, 
and quantified within less than 35 minutes, permitting rapid clinical assessment of a 
patient’s HbS burden and the adjustment of therapeutic interventions. This capability could 
be especially useful for patients on chronic transfusion therapy since, unlike conventional 
measures of %HbS, the paper-based test could determine the current %HbS level in time to 
assist the clinician in making decisions about current transfusion volume and subsequent 
transfusion frequency to maintain a target HbS level.
The paper-based assay for HbS quantification offers obvious advantages for resource-
limited settings. The low cost of the assay and its technical simplicity are major advantages 
in environments in which clinical resources, a reliable stream of specialized supplies for 
complex medical testing, and training for clinical and laboratory personnel are deficient. 
This assay is highly portable and can be set up quickly in any clinical setting, including 
those in which the supply of electricity may be uncertain. A major barrier to the 
implementation of transfusion and hydroxyurea therapies in resource-limited settings is the 
inability to monitor their efficacy in a timely manner that could influence patient care. The 
use of this assay could therefore make chronic transfusion therapy targeting a specific %HbS 
level, such as for primary or secondary stroke prophylaxis, more feasible in such settings. It 
can also be used in conjunction with other simple measurements (e.g. hemoglobin 
concentration and patient clinical status) to indirectly monitor the efficacy of HbF induction 
with hydroxyurea therapy since the reduction of %HbS in patients on hydroxyurea correlates 
with the degree of HbF induction.
There are a few technical limitations to the paper-based assay. The most prominent of these 
is that conditions resulting in clotting of blood samples can affect the quantification of HbS 
in the sample. In our validation cohort of 88 patient samples, the presence of clots in the 
samples resulted in greater deviation of the value for %HbS determined by the paper-based 
assay from that measured by hemoglobin electrophoresis. Secondly, the paper-based assay is 
not as accurate as more technically complex methods of HbS quantitation, especially at very 
high HbS levels, though this inaccuracy is relatively minor. Thirdly, very high levels of HbF 
(such as those found in newborns) may interfere with the polymerization of HbS and 
therefore decrease the accuracy of the assay. Finally, the assay in its current form cannot 
distinguish between non-pathological soluble hemoglobins, such as HbA, HbA2, and HbF, 
and those that can cause SCD in association with HbS, such as HbC or HbD. As such, the 
utility of this assay is currently limited to patients with homozygous sickle cell disease and 
Sβ0 thalassemia. Of note, however, patients with homozygous sickle cell disease and Sβ0 
thalassemia constitute the majority of all sickle cell patients (>70% in the United States and 
over 95% in many sub-Saharan African countries(16)) and are also the two most severe 
forms of the disorder with the most pressing need for clinical intervention.
In summary, we have developed a new, rapid, inexpensive paper-based assay for the 
quantification of %HbS in blood samples from patients with sickle cell disease. The assay 
determines %HbS across a wide range of values with a high degree of accuracy relative to 
hemoglobin electrophoresis and is unaffected by variations in overall hemoglobin 
concentration or the presence of HbA or HbF in the patient sample. Our assay has obvious 
applications in resource-limited settings and could be an important step towards making 
Piety et al. Page 7
Am J Hematol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
chronic transfusion therapy and hydroxyurea therapy feasible in such settings. The assay 
could also be useful in resource-rich settings by permitting more rapid and less expensive 
monitoring of response to these therapies, thus improving clinical care and reducing costs 
associated with the management of sickle cell disease.
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Figure 1. 
Schematic illustration of the paper-based HbS assay and the characteristic blood stains. (a) 
To perform the assay a 20 μL droplet of blood mixed with Hb solubility buffer (phosphate 
buffer containing saponin and sodium hydrosulfite) is deposited on chromatography paper, a 
blood stain is allowed to form (polymerized deoxy-HbS is trapped in the paper mesh and 
soluble forms of Hb are wicked laterally), and the stain is scanned and analyzed 
automatically to estimate %HbS in the sample. (b) Characteristic blood stains produced on 
paper by samples with various %HbS. Scale bar is 1 cm.
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Figure 2. 
Using a blood stain to estimate %HbS. (a) Schematic illustration of image analysis 
algorithm. (a-i) Centroid of the blood stain (marked by a cross) is automatically identified 
by the algorithm using contrast stretching and thresholding. (a-ii) The center spot (area 
inside dashed circle) and (a-iii) the peripheral ring (area between dashed circles) are 
extracted from the image through application of binary masks centered on the centroid of the 
stain. Mean color intensities of the center spot (IC) and the peripheral ring (IR) are extracted 
from the standardized blood stain. (b) Dependence of IC/IR on %HbS for a series of 
reconstituted blood (n = 5) samples with artificially adjusted %HbS varying from 0 to 75% 
(calibration curve, solid line). The values of the quotient of mean color intensities increased 
exponentially with increasing %HbS.
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Figure 3. 
Comparison of paper-based %HbS measurements with a reference method (hemoglobin 
electrophoresis). (a) %HbS for a group of patient samples (n = 88) was measured using the 
paper-based assay (Estimated %HbS) and conventional Hb electrophoresis (Actual %HbS). 
Estimated %HbS is highly correlated (R2 = 0.86) with actual %HbS (solid line = data trend 
line; dashed line = perfect correlation). Patient characteristics are indicated by dot color. (b) 
Bland–Altman plot shows strong agreement (SD difference = 7 %HbS) between estimated 
and actual %HbS (solid line = mean difference; dashed lines = ± 2 SD difference). The 
majority of the differences between actual and estimated %HbS (95.5%) are within 2 
standard deviations of the mean of the differences. Patient characteristics are indicated by 
dot color.
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fte
r (
Fin
al)
 
tr
an
sf
us
io
n.
 In
iti
al
 a
nd
 fi
na
l %
H
bS
 w
as
 m
ea
su
re
d 
by
 H
b 
el
ec
tro
ph
or
es
is 
an
d 
by
 th
e 
pa
pe
r-b
as
ed
 a
ss
ay
. A
 c
lin
ic
al
 e
sti
m
at
io
n 
of
 fi
na
l %
H
bS
 (b
ase
d o
n 
pa
tie
nt
 w
ei
gh
t, 
H
b 
co
nc
en
tra
tio
n 
an
d 
in
iti
al
 %
H
bS
 m
ea
su
re
d 
by
 H
b 
el
ec
tro
ph
or
es
is)
, u
sed
 to
 gu
ide
 tr
an
sfu
sio
n p
rac
tic
es,
 is
 sh
ow
n f
or 
co
mp
ari
so
n. 
Th
e 
m
ea
n
 d
iff
er
en
ce
 o
f c
ha
ng
e 
in
 %
H
bS
 m
ea
su
re
d 
by
 H
b 
el
ec
tro
ph
or
es
is 
an
d 
by
 th
e 
pa
pe
r-b
as
ed
 a
ss
ay
 is
 3
.9
 %
H
bS
. T
he
 m
ea
n 
di
ffe
re
nc
e o
f c
ha
ng
e i
n 
%
H
bS
 
m
ea
su
re
d 
by
 H
b 
el
ec
tro
ph
or
es
is 
an
d 
w
ith
 th
e 
cl
in
ic
al
 e
sti
m
at
io
n 
is 
3.
3 
%
H
bS
. T
he
 c
lin
ic
al
 e
sti
m
at
io
n 
ov
er
es
tim
at
ed
 th
e 
ch
an
ge
 in
 %
H
bS
 w
ith
 re
sp
ec
t t
o 
H
b 
el
ec
tro
ph
or
es
is 
in
 1
 o
f 5
 p
at
ie
nt
s. 
Th
e d
ec
re
as
e i
n 
%
H
bS
 m
ea
su
re
d 
by
 th
e p
ap
er
-b
as
ed
 as
sa
y 
w
as
 sm
al
le
r t
ha
n 
th
e d
ec
re
as
e i
n 
%
H
bS
 m
ea
su
re
d 
by
 H
b 
el
ec
tro
ph
or
es
is 
in
 5
 o
f 5
 p
at
ie
nt
s.
H
b 
el
ec
tro
ph
or
es
is
Cl
in
ic
al
 es
tim
at
io
n
Pa
pe
r-
ba
se
d 
as
sa
y
Pa
tie
nt
In
iti
al
 %
H
bS
Fi
na
l %
H
bS
C
ha
ng
e i
n 
%
H
bS
In
iti
al
 %
H
bS
Fi
na
l %
H
bS
C
ha
ng
e i
n 
%
H
bS
In
iti
al
 %
H
bS
Fi
na
l %
H
bS
C
ha
ng
e i
n 
%
H
bS
1
41
.2
27
.8
−
13
.4
41
.2
32
.1
−
9.
1
34
.3
22
.8
−
11
.5
2
30
.5
20
.2
−
10
.3
30
.5
22
.4
−
8.
1
26
.3
20
.4
−
5.
9
3
43
.5
30
.4
−
13
.1
43
.5
34
.4
−
9.
1
30
.4
24
.7
−
5.
7
4
33
.7
23
.2
−
10
.5
33
.7
21
−
12
.7
32
.3
22
.1
−
10
.2
5
33
.3
19
.7
−
13
.6
33
.3
23
.4
−
9.
9
21
.8
13
.6
−
8.
2
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